NasdaqGM:XLRN

Stock Analysis Report

Executive Summary

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Acceleron Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.1%

NasdaqGM:XLRN

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-4.1%

NasdaqGM:XLRN

-7.3%

US Biotechs

0.3%

US Market

XLRN outperformed the Biotechs industry which returned -8% over the past year.

XLRN underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

XLRNIndustryMarket
7 Day1.1%1.5%0.9%
30 Day9.9%2.2%-1.9%
90 Day7.5%3.5%1.6%
1 Year-4.1%-4.1%-6.5%-7.3%2.6%0.3%
3 Year50.5%50.5%8.9%5.2%41.0%31.8%
5 Year62.9%62.9%6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Acceleron Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acceleron Pharma undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Acceleron Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).

Acceleron Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Acceleron Pharma is loss making, we can't compare its value to the US Biotechs industry average.

Acceleron Pharma is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Acceleron Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

Acceleron Pharma is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Acceleron Pharma expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

43.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Acceleron Pharma's revenue is expected to grow significantly at over 20% yearly.

Acceleron Pharma's earnings are expected to grow significantly at over 20% yearly.

Acceleron Pharma's revenue growth is expected to exceed the United States of America market average.

Acceleron Pharma's earnings growth is expected to exceed the United States of America market average.

Acceleron Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Acceleron Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Acceleron Pharma performed over the past 5 years?

-20.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Acceleron Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Acceleron Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Acceleron Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Acceleron Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Acceleron Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Acceleron Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Acceleron Pharma's financial position?


Financial Position Analysis

Acceleron Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Acceleron Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Acceleron Pharma has no debt.

Acceleron Pharma currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Acceleron Pharma has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Acceleron Pharma has sufficient cash runway for more than 3 years based on current free cash flow.

Acceleron Pharma has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 26% each year.


Next Steps

Dividend

What is Acceleron Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Acceleron Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Acceleron Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Acceleron Pharma has not reported any payouts.

Unable to verify if Acceleron Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Acceleron Pharma has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Acceleron Pharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Acceleron Pharma's salary, the management and board of directors tenure and is there insider trading?

5.7yrs

Average management tenure


CEO

Habib Dable (50yo)

2.7yrs

Tenure

US$4,333,647

Compensation

Mr. Habib J. Dable has been the Chief Executive Officer and President at Acceleron Pharma Inc. since joining in December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuticals Inc., ...


CEO Compensation Analysis

Habib's remuneration is about average for companies of similar size in United States of America.

Habib's compensation has increased whilst company is loss making.


Management Age and Tenure

5.7yrs

Average Tenure

57yo

Average Age

The average tenure for the Acceleron Pharma management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

8.4yrs

Average Tenure

61.5yo

Average Age

The tenure for the Acceleron Pharma board of directors is about average.


Insider Trading

Acceleron Pharma individual insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

SellUS$486,30028 Jun 19
Jean George
EntityIndividual
Role
Member of the Board of Directors
Director
Shares11,812
Max PriceUS$41.17
BuyUS$190,25017 Jun 19
Joseph Zakrzewski
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$38.05
BuyUS$30,366,85822 Jan 19
Celgene Corporation
EntityCompany
Shares706,206
Max PriceUS$43.00

Ownership Breakdown


Management Team

  • Kevin McLaughlin (63yo)

    Senior VP

    • Tenure: 8.8yrs
    • Compensation: US$1.54m
  • Tom Maniatis (76yo)

    Co-Founder

    • Tenure: 16.6yrs
    • Compensation: US$268.89k
  • Mark Ptashne

    Co-Founder and Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Sujay Kango (55yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.5yrs
    • Compensation: US$2.37m
  • Ravi Kumar (59yo)

    Chief Scientific Officer & Senior VP

    • Tenure: 0.0yrs
    • Compensation: US$1.51m
  • John Quisel (48yo)

    Executive VP & Chief Business Officer

    • Tenure: 0.0yrs
    • Compensation: US$1.80m
  • Todd James

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0.0yrs
  • Habib Dable (50yo)

    CEO, President & Director

    • Tenure: 2.7yrs
    • Compensation: US$4.33m
  • Adam Veness

    VP, General Counsel & Secretary

    • Tenure: 0.0yrs
  • Kevin McManus

    Chief Human Resources Officer

    • Tenure: 0.6yrs

Board Members

  • Jean George (61yo)

    Director

    • Tenure: 14.6yrs
    • Compensation: US$283.89k
  • Richard Pops (57yo)

    Director

    • Tenure: 15.2yrs
    • Compensation: US$268.89k
  • Terry Kearney (64yo)

    Director

    • Tenure: 5.1yrs
    • Compensation: US$288.06k
  • Tom Maniatis (76yo)

    Co-Founder

    • Tenure: 16.6yrs
    • Compensation: US$268.89k
  • Bruce Spiegelman

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Mark Ptashne

    Co-Founder and Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Joe Zakrzewski (57yo)

    Director

    • Tenure: 8.4yrs
    • Compensation: US$290.97k
  • Joan Massague (66yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Francois Nader (62yo)

    Chairman of The Board

    • Tenure: 4.4yrs
    • Compensation: US$303.06k
  • Habib Dable (50yo)

    CEO, President & Director

    • Tenure: 2.7yrs
    • Compensation: US$4.33m

Company Information

Acceleron Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acceleron Pharma Inc.
  • Ticker: XLRN
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.457b
  • Shares outstanding: 52.83m
  • Website: https://www.acceleronpharma.com

Number of Employees


Location

  • Acceleron Pharma Inc.
  • 128 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XLRNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2013
0A3DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidate ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:25
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.